Raymond James raised the firm’s price target on Boston Scientific to $91 from $85 and keeps a Strong Buy rating on the shares. Boston Scientific’s Q2 results reinforce the primary bull narrative that Pulsed Field Ablation is emerging as the potential dominant technology in a $10B AF market that is accelerating, and the company is best positioned to benefit from this disruption, the analyst tells investors in a research note. The company is emerging as a mid-teens top-line/high-teens EPS grower, Raymond James contends.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific raises FY24 adjusted EPS view to $2.38-$2.42 from $2.29-$2.34
- Boston Scientific sees Q3 EPS 57c-59c, consensus 57c
- Boston Scientific reports Q2 adjusted EPS 62c, consensus 58c
- Boston Scientific Announces Results for Second Quarter 2024
- Notable companies reporting before tomorrow’s open